Ardian to acquire a stake in the Santé CIE Group alongside existing shareholders, HLD and UI Gestion

Ardian

Ardian will accompany the Santé Cie Group and its subsidiaries, Elivie and Asdia, in their international expansion and enlarging their expertise in the home medical assistance market

Paris, January 17, 2020 – Ardian, a world-leading private investment house, today announces that it has signed an agreement to acquire a majority stake in Santé Cie, a specialist in home medical assistance. Ardian will invest alongside HLD and UI Gestion, company shareholders since 2015, and the management team, to continue the consolidation of the French market and develop internationally.

With this investment, Ardian will enter the home medical assistance market. It offers the Group the opportunity to operate in a new, particularly attractive healthcare segment, while having a very positive social and societal impact. Santé Cie’s business addresses deep demographic, sociological and health challenges tied to an ageing population, an increasing prevalence of chronic illnesses, and a medical desertification in French rural areas.

Through its two operating networks, Elivie and Asdia, Santé Cie is among the most dynamic players in the home medical assistance sector in France. As a multi-specialist, it addresses the needs of patients in respiratory assistance, insulin therapy, perfusion, nutrition, post-operative care and wound treatment and healing. The company accompanies more than 150,000 patients annually and reported revenue of €240 million in 2019. It has nearly 1,700 employees and its 80 agencies offer services throughout France.

This transaction remains subject to antitrust approval and the opinion of the work council.

Larbi Hamidi, Chairman of Santé Cie: “This is a new impetus for our business. We’ll be able to actively contribute to consolidating the French market and launching our European expansion, but also investing in innovative solutions to improve the efficiency of care pathways in the face of new challenges posed by connected healthcare and telehealth.”

Jean-Bernard Lafonta, Chairman of HLD Europe, said: “We’re proud of Santé Cie’s journey since 2015 to have become one of the leading home medical assistance players in France. We’re delighted to continue our commitment alongside Santé Cie’s management to develop the business internationally and explore promising new segments such as dialysis at home.”

Olivier Jarrousse, Managing Partner of UI Gestion, added: “We’re very pleased with Santé Cie’s progress over the past 5 years and we wish to continue our active contribution to the Group’s development.”

Yann Bak, Managing Director in the Ardian Buyout team, said: ” We’re proud to enter Santé Cie’s share capital alongside existing shareholders and are confident that home medical assistance providers, by assisting patients and ensuring they are monitored by practitioners, have a role to play in the French healthcare value chain .”

Nicolas Darnaud, Managing Director in the Ardian Buyout team, added: “Santé Cie’s strong competitive advantages, its management, its scalable structure, its proven expansion and diversification capabilities, and its many growth options give it significant room for further growth in a fast-expanding market.”

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$96bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 640 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.Follow Ardian on Twitter @Ardian

ABOUT SANTE CIE

Created in 2016, Santé Cie is the third largest home healthcare provider in France, through its two operating networks Elivie and Asdia.
With the trust of healthcare professionals, the company supports nearly 150,000 home care patients, both children and adults, across France every day. It covers a wide range of therapeutic segments including perfusion, nutrition, insulin therapy, the treatment of Parkinson’s disease, respiratory assistance and wound treatment and healing.
By means of a medical prescription, the Elivie and Asdia teams set up all equipment required at home for the care of patients with chronic or acute illnesses. By ensuring the home care pathway, training and patient support and monitoring, the teams provide solutions to simplify and secure patient care at home, in constant contact with prescribers and in coordination with their entourage and all participants in the care chain (pharmacists, nurses, physiotherapists, etc.)
Santé Cie has nearly 1,700 employees across 80 agencies throughout France, through its Elivie and Asdia networks.

ABOUT HLD

Created in 2010 by Jean-Philippe Hecketsweiler, Jean-Bernard Lafonta and Philippe Donnet, HLD has experienced remarkable growth in the investment capital sector. The investment holding company now has 12 companies in France and Europe (including Tessi, Kiloutou, Coyote, Santé Cie and Rafaut), representing combined revenue of almost €2 billion and 17,000 employees. True to the wishes of its shareholders, which include many European entrepreneurs, including the Decaux, Dentressangle and Claude Bébéar families, HLD invests without any time constraints. This has enabled strong ties to be forged with portfolio company management, and HLD to support the long-term development of companies in Europe and internationally.
The HLD teams are currently present in Europe: Luxembourg, Paris, Milan and Zurich.

ABOUT UI GESTION

A historical investment capital player for 50 years, UI Gestion is an independent management company managing more than €650 million on behalf of leading institutional investors, entrepreneurs and Family Offices.

Independent since 2004, with a regional coverage since 2010 (Paris, Nantes, Rennes, Rheims, Strasbourg and Lille), UI Gestion specializes in developing SMEs and helps their management implement growth projects and buyout and growth transactions. With the UI Academy, management benefit from complementary tools to strengthen the strategic definition of their projects and operational implementation.

Over the past 15 years, UI Gestion has raised more than €1 billion across three investment platforms (regional, national, sector-based) and has supported more than 130 companies, primarily in the health care, agro-business and equipment manufacturing sectors.

LIST OF PARTIES INVOLVED

Ardian team: Yann Bak, Nicolas Darnaud, Nicolas Kassab, Maxime Debost
M&A Advisor: BNP Paribas (Sylvina Mayer, Marc Walbaum, Sammy Lamali, Clara Blandeau)
Commercial and strategic advisor: LEK (Arnaud Sergent, Serge Hovsepian, Leonore Bosch, Servane Perrot)
Financial DD: 8advisory (Christophe Delas, Christian Berling, Nicolas Bassi)
Legal and Tax Advisor: Latham & Watkins (Gaëtan Gianasso, Thimothée Brunello, Mayssa Sader, Xavier Renard, Yann Auregan)
CSR Advisor: Indefi (Emmanuel Parmentier, Charlotte Salmon)
IT Advisor: 8advisory IT (Jean-Christophe Fuzzati)
Digital Advisor: Singulier (Rémi Pesseguier, Diane Levy)HLD team: Jean-Bernard Lafonta, Maxence Gailliot, Julia Marc
UI Gestion team: Olivier Jarrousse, Sébastien Alauzet, Edouard Vilmer
M&A advisor to the seller: Rothschild (Laurent Baril, Robert Rozemulder)
Financial DD: Accuracy (Arnaud Lambert, Marie Madelpuech)
Legal Advisor: Weil, Gotshal & Manges (Alexandre Duguay, Pierre-Alexandre Khan, Come Wirz, Romain Ferla, Anne-Laila Abback, Cassandre Porgès, Timothée Buchet)

PRESS CONTACTS

Santé Cie
Severine Duhr
ARDIAN
Image 7
Anne-Charlotte Creac’h
Tel: 01 53 70 94 21
accreach@image7.fr
Flora Larger
Tel: 01 53 70 74 90
flarger@image7.fr

Categories: News

Tags:

Montagu to acquire the OEM business of RTI Surgical Holdings

Montagu

Montagu Private Equity (“Montagu”), a leading European private equity firm, announces that it has agreed to acquire the OEM, sports and reconstructive surgery implants divisions of RTI Surgical Holdings (the “OEM business”).

RTI’s OEM business designs, develops, manufactures and distributes biologic, metal and synthetic implants for a global customer base. Its implants are used in a variety of surgical procedures including orthopaedic, spine, sports medicine, general surgery and trauma.

RTI Surgical Holdings was established in the 1990s as a small tissue bank at the University of Florida. Since then, it has grown both organically and through acquisitions to become a leading surgical implants business that enjoys long-term relationships with blue-chip customers. Headquartered in Florida, US, the business has four manufacturing sites located across Germany and the US.

Guillaume Jabalot, Director at Montagu, said: “As a strong, resilient business that is well-positioned to capitalise on accelerated growth opportunities, RTI’s OEM business is an excellent fit for Montagu’s investment strategy. We look forward to working with Olivier and the team to support the business in this exciting next chapter of growth, maintaining its ethos of exceptional service and innovation”.

Olivier Visa, President of RTI’s OEM business, said: “We are thrilled about Montagu’s purchase of the OEM business. We have built a world-class design, development and manufacturing competency with demonstrated expertise across tissue, biologics and hardware with a tremendous team and a customer base of leading medical technology companies. We look forward to working with Montagu in driving the growth of the business and deepening the significant expertise and core competencies we have developed to serve more patients”.

The transaction is subject to approval from RTI Surgical Holdings’ shareholders, customary regulatory approvals and the satisfaction of customary closing conditions and is targeted to close in the first half of 2020.

This is Montagu’s second carve-out transaction announcement in four months. The firm recently completed its acquisition of Jane’s Group from IHS Markit in December 2019.

Weil, Gotshal & Manges LLP acted as legal advisors to Montagu.

Categories: News

Tags:

GHO Capital acquires Ardena, a leading CDMO providing early stage drug development and manufacturing for small-to-mid sized biopharma

Mentha Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.

Ardena is a multi-service CDMO, assisting small-to-mid sized biopharma with services spanning the full development life cycle. The Company offers a comprehensive ‘Make, Analyse, File’ model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development. Headquartered in Belgium, the company operates across several sites in the Netherlands, Sweden and Latvia.

With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 300 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform.

With extensive sectoral expertise and network in the global biopharma industry, the GHO team will support management in accelerating Ardena’s plan to enable customers to take a molecule from ‘target to clinic’ with a single outsourced drug development service provider.

GHO plans to further strengthen Ardena’s broad service proposition through organic and inorganic opportunities, adding to both the Company’s offering and international footprint.

The Company is well-positioned to benefit from sector trends as an increasing number of biopharma companies outsource large parts of their early stage drug development work to highly specialised CDMOs.

Harry Christiaens, CEO of Ardena, commented: “With their deep expertise in the Pharma sector, we are excited now to partner with GHO as we continue our international growth. Ardena and GHO are fully committed to the science-led approach that delivers valuable solutions for our biopharma customers globally.”

The Partners at GHO Capital, commented: “We are delighted to have the opportunity to work with the Ardena team. Operating within a highly fragmented market, Ardena is the market leading platform from which to build a fully integrated early stage CDMO, serving Biopharma clients globally.”

Gijs Botman, Partner of Mentha Capital, commented: “Ardena has grown from a Ghent-based business to become a leading early-stage, multi-service CDMO in Western Europe. After successfully completing and integrating four acquisitions, the company is now ready for a new growth phase. We had a fantastic journey with the Ardena team, and we are confident that GHO Capital is the right partner to support their ambitions going forward.”

LinkedIn

Categories: News

Tags:

IK Investment Partners to sell CID Lines

ik-investment-partners

Ecolab Inc. announced today it reached an agreement to acquire the CID Lines group (“the Group”), from the IK VII Fund, advised by IK Investment Partners (IK), and the other shareholders. Completion of the transaction is subject to customary closing conditions, including approvals from applicable competition authorities. CID Lines is a hygiene and health solutions provider, principally focused on the animal health industry.

Founded in Belgium in 1989, CID Lines established itself as a leader in disinfectants for combatting infectious animal diseases. Today, the Group’s product range includes a variety of veterinary medicinal products as well as an extensive range of high-quality, branded biosecurity solutions for disinfection and cleaning procedures in farming environments.

Since partnering with CID Lines in January 2016, IK has supported the execution of a successful strategy that has realised continued strong growth. Through its expanding network, CID Lines serves customers across the globe and continues to enhance its base through its best-in-class commercial capabilities in combination with its excellent research & development and registration capabilities.

Remko Hilhorst, Managing Partner at IK Investment Partners and advisor to the IK VII Fund, commented: “CID Lines has made tremendous progress since we first partnered with them in 2016, cementing their position as a leader in the increasingly important market for biosecurity and immunity products that support reduced use of antibiotics in farm animals. We are grateful to have worked with such a dedicated team of professionals at CID Lines to help the business successfully expand its reach and product range. We wish them every success in the future and look forward to seeing how the Company develops.”

Koen Brutsaert, founder and CEO at CID Lines commented: “CID Lines showed excellent growth the last three years. The drivers behind this growth were continued investments in new products, registrations and our salesforce.  IK has been very supportive of these investments in our growth, and we would like to thank them for this support.”

For further questions, please contact:

IK Investment Partners
Remko Hilhorst, Managing Partner
+31 208 909210

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 130 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

About CID Lines
Founded in Belgium in 1989, CID established itself as a leader in disinfectants for combatting infectious animal diseases. Today, the Group’s product range includes a variety of veterinary medicinal products as well as an extensive range of high-quality, branded biosecurity solutions for disinfection and cleaning procedures in farming environments.

Categories: News

Tags:

EQT invests in Asia based Health Management International

eqt

  • EQT Mid Market Asia invests in Health Management International, a reputable private healthcare provider with regional presence in Singapore, Malaysia and Indonesia
  • EQT will support Health Management International in realizing its full potential while scaling the Company’s platform in the region, organically and by exploring potential future acquisition opportunities
  • Health Management International was delisted from the Singapore Exchange on 24 December 2019

The EQT Mid Market Asia III fund (“EQT Mid Market Asia” or “EQT”) today announced its investment in Health Management International Ltd (“HMI” or the “Company”).

Founded in 1998, HMI is a regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Company is headquartered in Singapore and is led by an experienced management team and has a board with vast experience in developing and growing healthcare businesses in the region. The Company’s two tertiary hospitals in Malaysia, Mahkota Medical Centre and Regency Specialist Hospital, which are known for their clinical quality and breadth of specialties and subspecialties, attract medical tourists from all around Southeast Asia and serve approximately 100,000 international patients per year.

HMI has a strategy of investing in its facilities and service offerings and has further expanded its healthcare platform through investments in the first private one-stop ambulatory care center in Singapore, StarMed Specialist Centre, and a General Practice clinic chain in Singapore, OneCare Medical.

EQT will support HMI in realizing the full potential of its existing healthcare businesses, while investing further in capacity and capabilities. EQT plans to back the Company’s accelerated growth trajectory, both organically and by exploring potential acquisition opportunities. HMI will also be able to leverage on EQT’s deep healthcare sector expertise, global network and vast experience rolling out digitalization initiatives.

The investment in HMI is in line with EQT’s thematic approach. HMI participates in the development, planning and implementation of sustainable strategies and engages in numerous community initiatives which include medical screenings and treatments, promoting wellness and preventive healthcare.

Chin Wei Jia, Group CEO at HMI, commented: “We are excited to welcome EQT as our new partner for the next chapter of HMI’s development. EQT made a strong impression on us from the outset with their strategic approach and deep experience across the various healthcare ecosystems globally. Together, we will be able to accelerate HMI’s growth by focusing on providing quality healthcare to become one of the leading private healthcare providers in the region.”

Brian Chang, Partner at EQT Partners, Investment Advisor to EQT Mid-Market Asia, commented: “HMI is a well-established healthcare group with a high-quality, talented team and a solid track record in the region. EQT is excited to partner with HMI and support the next chapter of its growth journey. Going forward, the joint focus will be on scaling HMI’s operations in the region with its differentiated, passionate and hands-on approach while continuing to deliver high quality healthcare to its customers.”

Contact
Brian Chang, Partner at EQT Partners, Investment Advisor to EQT Mid Market Asia, +65 6595 1830
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on Twitter and LinkedIn

About Health Management International
HMI is a growing regional private healthcare provider with a presence in Singapore, Malaysia and Indonesia. HMI owns two tertiary hospitals in Malaysia, as well as a one-stop ambulatory care centre, healthcare training centre and a stake in a General Practice clinic chain in Singapore. HMI also has a network of representative offices in Indonesia, Malaysia and Singapore. HMI has more than 500,000 patients per annum, with over 200 practicing doctors and 1,800 staff.

More info: www.hmi.com.sg

Categories: News

Tags:

EQT invests in SHL Medical, a world-leading provider of drug delivery solutions

eqt

  • EQT acquires minority stake in SHL Medical, a world-leading manufacturer of advanced drug delivery systems such as autoinjectors
  • SHL is a pioneer and technology frontrunner in the self-injection industry, promoting well-being for all by allowing patients to safely self-administer medications at home
  • EQT will support SHL and the management team in its next phase of growth and innovation by leveraging EQT’s healthcare expertise, local angles and digital capabilities

The EQT VIII Fund (“EQT”) today announced that it has entered into an agreement to acquire a minority stake in SHL Medical (“SHL” or “the Company”). SHL was founded in Asia in 1989 with the goal of combining world-class manufacturing in Taiwan with the strengths of international management practices. The Company launched its first autoinjector in 1996 and today, SHL is a world-leading provider of drug delivery solutions.

Headquartered in Switzerland, SHL serves as a partner to global pharmaceutical companies and biotech firms. The Company has a global presence with offices and operations in Europe, Asia and the US, employing approximately 5,000 people worldwide. SHL’s management has been executing a strategic agenda focused around growth, innovation, digitization as well as operational and manufacturing excellence. EQT intends to support SHL in its next development phase, building on the current direction taken by the Company’s management.

SHL’s products enable effective and precise delivery of highly complex biologics and biosimilar drugs to patients worldwide. They empower patients through safe self-administration of medication in the comfort of their homes. Therefore, the investment is in line with EQT’s thematic approach and mindset of making a positive impact in society with everything it does, guided by the United Nations Sustainable Development Goals (SDGs).

Ulrich Faessler, CEO of SHL, commented: “We are excited to have EQT as our new shareholder and look forward to working together in the next development phase of SHL. EQT’s entrepreneurial heritage and investment approach are a great cultural fit for SHL. Together, we will continue to build and grow the company in order to provide the best solutions for our customers.”

Andreas Aschenbrenner, Partner at EQT Partners and Investment Advisor to EQT VIII, added: “We are impressed by SHL’s entrepreneurial spirit and the management team’s achievements in growing the firm into an industry leader with deep innovation and manufacturing capabilities. EQT looks forward to working together with SHL’s management team in this attractive growth investment opportunity.”

The proposed transaction is subject to customary regulatory approvals.

With this transaction, EQT VIII is expected to be 70-75 percent invested.

Contacts
Andreas Aschenbrenner, Partner at EQT Partners and Investment Advisor to EQT VIII, +49 89 25 54 99 0
EQT Press office, +46 8 506 55 334

About EQT
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on Twitter and LinkedIn

About SHL Medical
SHL Medical designs, develops and manufactures advanced drug delivery devices, such as autoinjectors, pen injectors and advanced inhaler systems, and provides final assembly, labeling, and packaging services for pharma and biotech companies worldwide. Headquartered in Switzerland with locations in Taiwan, Sweden and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

More info: www.shl.group
Follow SHL Medical on Twitter and LinkedIn

Categories: News

Tags:

EQT Infrastructure enters into a Scheme Implementation Agreement with Metlifecare

eqt

  • Asia Pacific Village Group Limited (“APVG”), an entity owned by EQT Infrastructure IV fund and managed by EQT Fund Management S.à r.l. (“EQT Infrastructure IV”) has entered into a Scheme Implementation Agreement (“SIA”) with Metlifecare, to acquire 100% of Metlifecare shares by way of a scheme of arrangement (“Scheme”), subject to certain conditions.
  • Transaction consideration of NZ$7.00 per share (“Offer Price”), giving a total consideration of approximately NZ$1.5 billion (“Consideration”).
  • Offer Price represents a premium of 38% to Metlifecare’s closing share price of NZ$5.08 per share on 19 November 2019, the closing price prior to the announcement of EQT Infrastructure IV initial indicative non-binding offer, and represents a 1.0x P / NTA[1].
  • APVG has entered into a voting deed with Metlifecare’s largest shareholder, New Zealand Superannuation Fund Nominees Limited (“NZSF”), which holds 19.86% of Metlifecare’s shares.
  • Certain other Metlifecare shareholders collectively representing approximately 22% of the register have indicated to EQT Infrastructure IV their current intention to vote in favor of the Scheme, in the absence of a superior proposal.

Auckland, New Zealand. APVG, an entity owned by EQT Infrastructure IV has entered into a Scheme Implementation Agreement (“SIA”) with Metlifecare, to acquire 100% of Metlifecare shares by way of a scheme of arrangement (“Scheme”), subject to certain conditions.

APVG has entered into a voting deed with Metlifecare’s largest shareholder, New Zealand Superannuation Fund Nominees Limited (“NZSF”), which holds 19.86% of Metlifecare’s shares.  Under the voting deed NZSF has agreed, among other things, to vote in favour of the Scheme subject to certain terms and conditions.  A copy of that voting deed has been released to the market through the substantial product holder notice issued by APVG and EQT Infrastructure IV.

In addition, Metlifecare shareholders collectively representing approximately 22% of the register have indicated to EQT Infrastructure IV their current intention to vote in favour of the Scheme, in the absence of a superior proposal.

Metlifecare is a leading New Zealand owner and operator of retirement villages, providing rewarding lifestyles and outstanding care to more than 5,600 New Zealanders. Established in 1984, it currently owns and operates a portfolio of 25 villages in areas with strong local economies, supportive demographics and high median house prices, located predominantly in New Zealand’s upper North Island.

EQT is a differentiated global investment organization that invests in good companies across the world with a mission to help them develop into great and sustainable companies. By providing access to ownership skills and operational expertise, EQT helps acquired companies grow and prosper. Development and growth are at the core of the value creation, with digitalization and sustainability being key future-proofing drivers. Portfolio companies owned by the funds of EQT have, on average, increased sales by 12%, the number of employees by 10% and profitability by 11% per annum during the funds’ ownership.

Fabian Gröne, Partner at EQT Partners and Investment Advisor to EQT Infrastructure IV, said: “We are delighted about the opportunity to partner with Metlifecare and are fully committed to supporting Metlifecare and its management team to embark on this exciting journey to develop and operate high-quality retirement villages and continue to provide the exceptional care to New Zealanders which Metlifecare is known for.”

EQT Infrastructure IV will be funding the Consideration and has total committed capital of EUR 9 billion.

The transaction will be implemented by a scheme of arrangement, a court-supervised process under which a meeting of shareholders will be held to vote on the transaction.

Scheme Implementation Agreement

The Scheme is subject to customary conditions including shareholder approval, High Court approval and Overseas Investment Office consent and no Material Adverse Change (as defined in the SIA). It is currently contemplated that the Scheme will be implemented in May 2020.

The Scheme also contains customary exclusivity provisions in favour of APVG, including “no shop, no talk and no due diligence” restrictions. These restrictions are subject to exclusions which permit the Metlifecare Board to engage on a competing proposal which is (or is reasonably capable of becoming) a superior proposal, subject to prior notifications being made to EQT Infrastructure IV and to EQT Infrastructure IV’s right to match any such proposal.

EQT Infrastructure IV is being advised by Goldman Sachs and Bell Gully.

With this transaction, EQT Infrastructure IV is expected to be 55-60 percent invested (including closed and/or signed investments, announced public offers, if applicable, and less any expected syndication), subject to shareholder and Court approval.

Contact
International media inquiries: EQT Press Office press@eqtpartners.com +46 8 506 55 334
New Zealand media inquiries: David Lewis david@thompsonlewis.co.nz +64 21 976 119
Australian media inquiries: Jim Kelly jim@domestiqueconsulting.com.au +61 412 549 083

About EQT
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

EQT has extensive experience and an excellent track record in the healthcare sector and is one of the largest private equity investors in the healthcare sector in Europe with an unparalleled network of advisors within the EQT Network. Some of EQT’s notable investments in the sector include Charleston, a buy-and-build strategy in the German nursing home care market, and I-MED, a leading diagnostic imaging provider in Australia.

More info: www.eqtgroup.com
Follow EQT on Twitter and Linkedin

About Metlifecare
Metlifecare is a leading New Zealand owner and operator of retirement villages, providing rewarding lifestyles and outstanding care to more than 5,600 New Zealanders. Established in 1984, it currently owns and operates a portfolio of 25 villages in areas with strong local economies, supportive demographics and high median house prices, located predominantly in New Zealand’s upper North Island.

More info: www.metlifecare.co.nz

[1] Net Tangible Assets (“NTA”) of NZ$6.96 per share as of 30 June 2019.

Categories: News

Tags:

Metro Pacific Hospitals Completes Investment by KKR

KKR

MANILA, Philippines–(BUSINESS WIRE)–Dec. 8, 2019– Metro Pacific Investments Corporation (“MPIC”) (PSE: MPI), global investment firm KKR, and GIC, Singapore’s sovereign wealth fund, today announced the completion of investments in Metro Pacific Hospital Holdings, Inc. (“Metro Pacific Hospitals” or the “Company”) by KKR and an affiliate of GIC (“GIC”). These were made through a series of transactions in common shares in Metro Pacific Hospitals and in mandatorily exchangeable bonds issued by MPIC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191208005083/en/

Proceeds from the sale of shares in the Company will be used to support Metro Pacific Hospitals’ potential investments in additional hospitals and new healthcare businesses. The capital will also be used to grow the Company’s existing subsidiaries, associates, and joint ventures.

Metro Pacific Hospitals is the operator of the largest private hospitals and healthcare network in the Philippines in terms of authorized bed capacity and revenues, with interests in 14 hospitals and approximately 3,200 beds across the country. The Company is focused on delivering high-quality healthcare solutions to patients at a time when more Filipinos are seeking premium medical services, driven by rising per capita incomes and rapid urbanization.

Manuel V. Pangilinan, Chairman of MPIC and Metro Pacific Hospitals, said, “We welcome KKR and GIC as investors who not only have established track records of helping healthcare companies to meet their growth ambitions, but also have full confidence in Metro Pacific Hospitals’ potential to provide even more critical healthcare services to patients across the Philippines. Today marks the start of a new and exciting chapter for Metro Pacific Hospitals.”

Augusto P. Palisoc Jr., President & CEO of Metro Pacific Hospitals, added, “The Philippine healthcare industry is poised for tremendous growth given the increasing demand for hospitals, clinics, and facilities that provide premium medical services. With this new investment, coupled with the expertise that KKR and GIC bring to Metro Pacific Hospitals, we will be in an even stronger position to meet patients’ needs and capture new opportunities through organic expansion, acquisitions and investments, and the adoption of new technologies.”

Jose Ma. K. Lim, President and CEO of MPIC, said, “The MPIC team is proud of Metro Pacific Hospitals and is pleased to have created and grown one of the largest and strongest hospital groups in the Philippines. We anticipate Metro Pacific Hospitals will continue to go from strength to strength alongside KKR and GIC, and we look forward to continuing our long-term partnership with the whole Metro Pacific team.”

Ashish Shastry, Co-Head of Asia Pacific Private Equity and Head of Southeast Asia at KKR, said, “Metro Pacific Hospitals is a world-class healthcare institution with a terrific team of doctors and medical practitioners who play a critical role in the lives of millions. We are excited to begin our work alongside this excellent team and look forward to supporting Metro Pacific Hospitals’ continued growth and development for healthcare providers and patients in the years to come.”

KKR made its investment from its flagship Asian Fund III.

About Metro Pacific Investments Corporation

Metro Pacific Investment Corporation is a publicly-listed, infrastructure investment firm in the Philippines, with holdings in Manila Electric Company, Global Business Power, Maynilad Water Services, Inc. and Metro Pacific Tollways Corporation. MPIC also holds investments in MPHHI, the Light Rail Manila Company and Metropac Movers Inc.

About Metro Pacific Hospital Holdings, Inc.

Metro Pacific Hospitals is the operator of the largest private hospitals and healthcare network in the Philippines in terms of authorized bed capacity and revenue, with interests in 14 hospitals nationwide, including eight hospitals in Metro Manila. The Company also has interests in an eight primary care clinics and eight cancer care centers, among other investments in allied healthcare services.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

About GIC

GIC is a leading global investment firm established in 1981 to manage Singapore’s foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate and infrastructure. In private equity, GIC invests through funds as well as directly in companies, partnering with its fund managers and management teams to help world class businesses achieve their objectives. GIC has investments in over 40 countries and has been investing in emerging markets for more than two decades. Headquartered in Singapore, GIC employs over 1,500 people across 10 offices in key financial cities worldwide.

For more information about GIC, please visit www.gic.com.sg or follow us on LinkedIn.

Source: KKR

Media:

For MPIC & Metro Pacific Hospitals:

David J. Nicol
EVP & Chief Financial Officer
Tel: +632 8888 0888

Augusto P. Palisoc, Jr.
CEO of MPHHI
Tel: +632 8888 0888

Melody M. Del Rosario
VP, PR & Corp. Comms.
Tel. +632 8888 0888

For KKR:

KKR Asia Pacific
Anita Davis
+852 3602 7335
anita.davis@kkr.com

KKR Americas

Kristi Huller & Cara Major
+1 212 750 8300
media@kkr.com

For GIC:

Mah Lay Choon
Senior Vice President
Corporate Affairs & Communications
+65 6889 6841
mahlaychoon@gic.com.sg

Wei Jun Ong
Associate
Corporate Affairs & Communications
+65 6889 8340
ongweijun@gic.com.sg

Categories: News

Tags:

EQT to sell Clinical Innovations

eqt

  • EQT Mid Market US and EQT Mid Market Asia III to sell Clinical Innovations, a leading global provider of medical devices for Labor & Delivery and Neonatal Intensive Care, to LABORIE for an Enterprise Value of USD 525m
  • During EQT’s ownership, Clinical Innovations has successfully transitioned from a distributor sales model to a direct sales force in select key markets, broadened its product portfolio in the Neonatal Intensive Care segment through product acquisitions and established a foothold in China

The EQT Mid Market US fund and the EQT Mid Market Asia III fund (jointly “EQT”) have entered into an agreement to sell Clinical Innovations (the “Company”) to LABORIE Medical Technologies (“LABORIE”) for an Enterprise Value of USD 525m. The EQT Mid Market US fund is the majority owner of Clinical Innovations.

Founded in 1993 and headquartered in Salt Lake City, Utah, Clinical Innovations is a leading global provider of medical devices for Labor & Delivery and Neonatal Intensive Care. The Company’s products, which include the Kiwi® Vacuum-Assisted Delivery System, Koala® Intrauterine Pressure Catheter and ebb® Complete Tamponade System, are used by clinicians in more than 90 countries to improve the lives of mothers and babies. Clinical Innovations also added SweetUms sucrose solution and the BoogieBaby oral and nasal suction device to its growing NICU product lineup earlier in December this year. Clinical Innovations operates a manufacturing facility in Utah and has approximately 250 employees around the world.

Together with the management team, EQT has supported Clinical Innovations in successfully transitioning from a distributor sales model to a direct sales force in select key markets, including parts of the United States, Western Europe and Australia. During EQT’s ownership, the Company has also successfully established a foothold in China and broadened its product portfolio within Neonatal Intensive Care.

“With the support of EQT, Clinical Innovations has significantly grown its global footprint and strengthened its product offering,” said Ken Reali, President and CEO of Clinical Innovations. “We look forward to continuing our growth journey with LABORIE and are confident that, together with our new partners, we will be well positioned to further positively impact mothers, babies and healthcare professionals on a large scale.”

“Clinical Innovations and the global network of clinicians who rely on its devices every day are crucial contributors to the health of mothers and babies,” said Brendan Scollans, Partner at EQT Partners and Investment Advisor to EQT Mid Market US. “We have been proud to support the development and growth of the company in partnership with the management team and look forward to following its continued success.”

“During EQT’s ownership, Clinical Innovations has strengthened its direct local presence in China, positioning the Company to capture future growth in one of the most promising markets,” said Jerry He, Partner at EQT Partners and Investment Advisor to EQT Mid Market Asia III. “LABORIE is a strong strategic fit for Clinical Innovations and we are confident that they will be an excellent partner for the Company.”

The transaction is subject to customary approvals and is expected to close in early 2020.

Moelis & Company LLC acted as financial advisor and Simpson Thacher & Bartlett LLP acted as legal advisor to EQT and Clinical Innovations.

Contact
US inquiries: Stephanie Greengarten, +1 646 687 6810, stephanie.greengarten@eqtpartners.com
International inquiries: EQT Press Office, +46 8 506 55 334, press@eqtpartners.com

About EQT
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on Twitter and LinkedIn

About Clinical Innovations
Founded in 1993, Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and neonatal intensive care. The company is a market-leader in several categories with products such as the Kiwi® Vacuum-Assisted Delivery System, SweetUms sucrose solution, BoogieBaby oral and nasal suction device, Koala® Intrauterine Pressure Catheter, ROM Plus® Rupture of Membranes Test, traxi® Panniculus Retractor, ClearView® Uterine Manipulator, ebb® Complete Tamponade System and the babyLance™ Safety heel stick. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. For more information, visit clinicalinnovations.com.

Categories: News

Tags:

Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock

Abingworth

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 19, 2019– Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the pricing of the previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $2.75 per share. Exicure has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover overallotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 23, 2019 subject to customary closing conditions.

Exicure expects to receive gross proceeds of $27.5 million from the sale of common stock in the offering, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by it. Exicure intends to use the net proceeds from the offering to advance AST-008 through a Phase 1b/2 clinical trial; to initiate a second arm in its Phase 1b/2 clinical trial in cutaneous squamous cell carcinoma; to develop an SNA-based therapeutic candidate for the treatment of Friedreich’s ataxia, initiate IND-enabling studies and advance it into Phase 1 clinical trials; to develop a second SNA therapeutic candidate for a neurology condition and initiate IND-enabling studies; and for general corporate purposes.

Guggenheim Securities is acting as sole book-running manager for the offering. Chardan is acting as lead manager for the offering. H.C. Wainwright & Co. and Ladenburg Thalmann are acting as co-managers for the offering.

The securities described above are being offered by Exicure pursuant to a shelf registration statement on Form S-3 (No. 333-230175) that was declared effective by the Securities and Exchange Commission (SEC) on July 24, 2019. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website located at www.sec.gov. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, from: Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.

Exicure Forward Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies, cash requirements and other matters as well as statements regarding the Company’s intention to conduct an offering and sale of securities, the size of the offering, the completion of the offering and the expected use of proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Exicure, Inc.

MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com

 

 

Categories: News

Tags: